Antibe Therapeutics Inc. (TSX: ATE.TO) Stock Competitors & Peer Comparison

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, ABT.TO has a market cap of 31B. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while ABT.TO trades at CA$17.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas ABT.TO's P/E ratio is 4.17. In terms of profitability, ATE.TO's ROE is -0.40%, compared to ABT.TO's ROE of -0.23%. Regarding short-term risk, ATE.TO is more volatile compared to ABT.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check ABT.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, VMD.TO has a market cap of 402.2M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while VMD.TO trades at CA$10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas VMD.TO's P/E ratio is 32.66. In terms of profitability, ATE.TO's ROE is -0.40%, compared to VMD.TO's ROE of +0.06%. Regarding short-term risk, ATE.TO is more volatile compared to VMD.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check VMD.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, PRN.TO has a market cap of 302M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while PRN.TO trades at CA$8.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas PRN.TO's P/E ratio is -6.11. In terms of profitability, ATE.TO's ROE is -0.40%, compared to PRN.TO's ROE of -0.62%. Regarding short-term risk, ATE.TO is more volatile compared to PRN.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check PRN.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, QIPT.TO has a market cap of 221.4M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while QIPT.TO trades at CA$4.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas QIPT.TO's P/E ratio is -15.56. In terms of profitability, ATE.TO's ROE is -0.40%, compared to QIPT.TO's ROE of -0.10%. Regarding short-term risk, ATE.TO is more volatile compared to QIPT.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check QIPT.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, TMD.TO has a market cap of 128.3M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while TMD.TO trades at CA$1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas TMD.TO's P/E ratio is -0.65. In terms of profitability, ATE.TO's ROE is -0.40%, compared to TMD.TO's ROE of +8.58%. Regarding short-term risk, ATE.TO is less volatile compared to TMD.TO. This indicates lower risk in terms of short-term price fluctuations for ATE.TO.Check TMD.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, NVCN.TO has a market cap of 110.8M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while NVCN.TO trades at CA$40.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas NVCN.TO's P/E ratio is -1.96. In terms of profitability, ATE.TO's ROE is -0.40%, compared to NVCN.TO's ROE of -1.21%. Regarding short-term risk, ATE.TO is more volatile compared to NVCN.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check NVCN.TO's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, PMED.CN has a market cap of 11.4M. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while PMED.CN trades at CA$0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas PMED.CN's P/E ratio is -2.75. In terms of profitability, ATE.TO's ROE is -0.40%, compared to PMED.CN's ROE of +0.93%. Regarding short-term risk, ATE.TO is more volatile compared to PMED.CN. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check PMED.CN's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, ASTI.CN has a market cap of 276K. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while ASTI.CN trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas ASTI.CN's P/E ratio is -0.43. In terms of profitability, ATE.TO's ROE is -0.40%, compared to ASTI.CN's ROE of +0.24%. Regarding short-term risk, ATE.TO is more volatile compared to ASTI.CN. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check ASTI.CN's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, IME.CN has a market cap of 162.5K. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while IME.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas IME.CN's P/E ratio is -0.04. In terms of profitability, ATE.TO's ROE is -0.40%, compared to IME.CN's ROE of +0.20%. Regarding short-term risk, ATE.TO is more volatile compared to IME.CN. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check IME.CN's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, MYTC.CN has a market cap of 159.4K. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while MYTC.CN trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas MYTC.CN's P/E ratio is -0.08. In terms of profitability, ATE.TO's ROE is -0.40%, compared to MYTC.CN's ROE of +0.60%. Regarding short-term risk, ATE.TO is more volatile compared to MYTC.CN. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check MYTC.CN's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, AVBT.CN has a market cap of 123.7K. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while AVBT.CN trades at CA$0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas AVBT.CN's P/E ratio is -0.20. In terms of profitability, ATE.TO's ROE is -0.40%, compared to AVBT.CN's ROE of +4.09%. Regarding short-term risk, ATE.TO is more volatile compared to AVBT.CN. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check AVBT.CN's competition here

Antibe Therapeutics Inc. (TSX: ATE.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ATE.TO stands at 15.6M. In comparison, HSM.TO has a market cap of 0. Regarding current trading prices, ATE.TO is priced at CA$0.30 on the TSX, while HSM.TO trades at CA$18.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ATE.TO currently has a P/E ratio of -0.84, whereas HSM.TO's P/E ratio is -1.73. In terms of profitability, ATE.TO's ROE is -0.40%, compared to HSM.TO's ROE of -2.91%. Regarding short-term risk, ATE.TO is more volatile compared to HSM.TO. This indicates higher risk in terms of short-term price fluctuations for ATE.TO.Check HSM.TO's competition here